HEP DART 2019 program

The scientific program of HEP DART 2019 consists of plenary lectures, invited speakers, oral abstracts, and special academic/industry sessions tackling the latest issues in drug development for viral hepatitis and chronic liver disease (NASH, fibrosis, HCC). This year's program also includes two special debates, a poster reception, multiple panel discussions, and plenty of opportunity for networking and dialogue amongst the delegates.


Here is what to expect:

  • 250+ Attendees

  • 40+ World-class invited key opinion leaders

  • 5 days of scientific programming 

  • No concurrent sessions

  • A Debate

  • 8 Panel discussions

  • 12+ Hours dedicated to networking

  • Academic-Industry sessions

  • CME accreditation


Stephen_Locarnini_1_lr_crop.jpg

William H. Prusoff HEP DART Lifetime Achievement Award

HEP DART 2019 is delighted to announce the selection of Dr. Stephen Locarnini as the recipient of the 2019 William H. Prusoff HEP DART Lifetime Achievement Award.

Please join us for a special award lecture by Dr. Locarnini on Monday December 09, 2019 entitled:

“Origins of the hepatitis B virus: Will the real “Australia Antigen” please stand up?” 


Highlights from the scientific program


State-of-the-Art lectures (*):

Current landscape of NASH, HCC and viral hepatitis*
Robert Wong, UCSF, USA 

Characteristics of patients with chronic hepatitis in the United States: Based on data from Hepatitis B Research Network*
Adrian Di Bisceglie, Saint Louis University, USA

Mechanisms of NAFLD development and therapeutic strategies **
Scott Friedman, Icahn School of Medicine at Mount Sinai, USA

Clinical update on drugs for HBV cure* 
Harry Janssen, University of Toronto, Canada 

What would an HBV cure look? Endpoints and clinical trial design towards a cure* 
Anna Lok, University of Michigan, USA

Molecular mechanisms of HBV cccDNA biosynthesis and transcription suppression by IFN-alpha*
Ju-tao Guo, Baruch S. Blumberg Institute of Living Science, USA

Dash for NASH cure*
Eduardo Martins, Allergan, USA

HBV vaccines: New and old*
Marion Peters, University of California San Francisco, USA

The use of systems biology in treatment of liver diseases*
Adil Mardinoglu, King's College London, UK

From liver disease to HCC: All roads lead to Rome*
T. Jake Liang, National Institutes of Health, USA

HDV epidemiology, pathogenesis, diagnosis and new treatments*
Stephan Urban, Deutsches Zentrum für Infektionsforschung, Germany

Hepatitis A pathogenesis*
Stanley Lemon, University of North Carolina at Chapel Hill, USA

Invited speaker lectures:

Facts and fiction in the epidemiology of chronic viral hepatitis
Robert Gish, Hepatitis B Foundation, USA

Elimination of HCV in Egypt: A global model
Manal El-Sayed, Ain Shams University, Egypt 

Colocation care model of HCV in people who inject drugs
Elana Rosenthal, University of Maryland, USA

PD-1 blockade recovers dysfunctional virus-specific B cells in chronic hepatitis B infection
Antonio Bertoletti, Duke-NUS Medical School, Singapore

Occult HBV infection
Teresa Pollicino, University Hospital of Messina, Italy

Lessons learned from HCV vaccine 
Andrea Cox, Johns Hopkins University, USA

Therapeutic vaccination in hepatitis B
Ulrike Protzer, Institute of Virology, Technische Universität München, Germany

Discovery of novel targets for treatment of NASH and liver fibrosis
Thomas Baumert, University of Strasbourg, France 

Genetic profiling and personalized medicine in HCC
Lewis Roberts, Mayo Clinic, USA

HBV co-infection with HIV or HCV
Mark Sulkowski, Johns Hopkins University, USA

Is shorter treatment for HCV and HBV possible?
Alan Perelson Los Alamos National Laboratory, USA

Antiviral therapies for HBV and HCV infection in the context of liver transplantation
Michael Manns, Hannover Medical School, Germany

Single hepatocyte co-infection in the context of HBV
Chloe Thio, Johns Hopkins University, USA 

NAFLD and the heart
Laurence Sperling, Emory University, USA

Five decades of HBV research
George Lau, Humanity and Health Medical Center, Hong Kong, China

Aramchol phase 3/4 outlook
Carol L. Brosgart, University of California San Francisco, USA

A gene editing approach to eliminate hepatitis B virus in vivo with an ARCUS meganuclease evolved to prevent off target cutting
Derek Jantz, Precision Biosciences, USA

Future direct acting antivirals in development: Janssen HBV pipeline
Tarik Asselah, University Paris Diderot, INSERM, France

Using HCV-Positive donors in uninfected recipients – conquests and cautions
Norah Terrault, University of California San Francisco, USA

NASH therapeutics in children
Saul Karpen, Emory University, USA

HEV as a global disease: From epidemiology to cure
Kenneth Sherman, University of Cincinnati, USA

preliminary Program Overview